



Method Development and validation of Levosalbutamol sulphate by Derivative Spectroscopy

Nyola Narendra*^{1, 2}, Govinda Samy Jeyabalan¹

1 Department of Pharmaceutical Analysis, Alwar Pharmacy College, Alwar, India.

2. Department of Pharmaceutical Sciences, Shridhar University, Pilani, India

Article history: Received: 2 January 2013, revised: 29 January 2013, accepted: 23 February 2013, Available online: 3 April 2013

Abstract

Plan: An analytical method for estimation of levosalbutamol in bulk and pharmaceutical formulation.

Preface: The developed method is simple, fast and accurate and can be used for routine analysis of Market formulations.

Methodology: In this study zero, first and second order derivative spectrophotometric method were developed for the estimation of Levosalbutamol sulphate. In zero order spectrophotometry, absorbance value was measured at 277nm. In first derivative spectrophotometry amplitudes were measured at 233nm. In second derivative spectrophotometry amplitudes were measured at 237nm. Calibration curves were linear between the concentration range of 20-60µg/ml, 5-30µg/ml and 35-60µg/ml respectively. The % RSD value is less than 2% and the recovery were near 100% for all methods.

Outcome: All the developed methods were applied on pharmaceutical formulations.

Key words: Spectrophotometric method, Levosalbutamol sulphate, Derivative spectroscopy.

1. Introduction

Levosalbutamol sulphate (LSS) is the R - enantiomer of short acting β_2 -adrenergic receptor agonist of Salbutamol. Chemical it is 4[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxy methyl) phenol and its Molecular formula $C_{13}H_{21}NO_3$, Molecular wt. 239.311 g/mol. As a bronchodilator, it is used to treat asthma and COPD^{1, 2}. Literature survey reveals that, only few spectrophotometric^{3, 4,5,6,7} and bio-analytical methods by HPLC was found using human plasma urine, blood and biological fluids^{8,9,10}, GC-MS-SIM¹¹ and HPLC¹² for the quantitative estimation of Levosalbutamol sulphate in bulk and pharmaceutical formulations have been developed. Hence an attempt has been made to develop new method for its estimation in bulk and pharmaceutical formulation with good accuracy, simplicity and precision.




Fig.1 Levosalbutamol sulphate



For Correspondence: narenyola2@gmail.com

Hygeia.J.D.Med. Vol.5 (1), April 2013

© 2013, Hygeia journal for drugs and medicines, All rights reserved. 2229 3590, 09756221

Researcher ID: C-2496-2013

2. Material and Methods

2.1 Apparatus

A Shimadzu model 1800 double beam UV/Visible spectrophotometer with spectral width of 1 nm, wavelength accuracy of ± 0.1 nm and a pair of 10 mm matched quartz cell was used to measure absorbance of all the solutions. Spectra were automatically obtained by UV-Probe system software (ver.2.34).

2.2 Reagents and Materials

All chemicals and reagents were used of AR grade. Authentic of LSS was obtained as gift samples from Cipla Pharmaceutical Pvt., Ltd. Mumbai.

2.3 Selection of detection wavelength

Solutions of drug were scanned over the range of 200-400 nm. It was observed that the drug showed considerable absorbance at 277nm, 232nm and 237nm for zero, first and second order were selected as the wavelength for detection. The spectra of LSS show in fig. 5, 6 and 7.

2.4 Preparation of standard stock solutions

LSS was weighed (100mg) and transferred to 100ml volumetric flasks and make up the volume up to the mark with distilled water and the final concentration of solution containing 1000 $\mu\text{g/ml}$ of LSS.

2.5 Preparation of working solutions

Aliquot from the stock solutions of LSS was appropriately diluted with distilled water to obtain working standard of LSS.

3. Method Development and Validation

The method was validated for accuracy, precision, linearity, detection limit, quantitation limit and specificity.

3.1 Linearity

The linearity of levosalbutamol was found to be 20-60 $\mu\text{g/ml}$, 5-25 $\mu\text{g/ml}$ and 35-55 $\mu\text{g/ml}$ for zero, first and second order respectively. The r^2 values were near about 0.999 for all orders which shows good correlation between analyte concentration and response area. The data of regression analysis was shown in table 1 and figure 2, 3, 4.

Table 1 Analytical performance parameters of levosalbutamol

Parameters	Zero order	First order	Second order
Wavelength Maximum	277	232	237
Linearity range (µg/ml)	20-60	5-30	35-65
Correlation coefficient	0.998	0.999	0.996
LOD (µg/ml)	1.84	1.18	2.13
LOQ (µg/ml)	5.48	3.57	6.45
Sandell's sensitivity (mg/cm ² /0.001 absorbance unit)	0.107	0.071	0.198




Fig.2: Calibration curve for zero order for levosalbutamol




Fig. 3 Calibration curve for first order for levosalbutamol




Fig. 4 Calibration curve for second order for levosalbutamol




Fig 5 .Zero order spectra of levosalbutamol




Fig 6 .First order spectra of levosalbutamol




Fig 7 Second order spectra of levosalbutamol

3.2 Precision

The %RSD obtained for repeatability studies were found to be -0.53-0.73 carried out by estimating response for levosalbutamol. The %RSD for intra-day and inter-day precision was found to be 0.154-1.13 and 0.21-1.5 respectively for levosalbutamol. The RSD values which are well below 2% indicate that the precision of the method is satisfactory. (Table 2 and 3).

Table 2 .Repeatability study for levosalbutamol

Parameters	Zero order (30µg/ml)	First order (10µg/ml)	Second order (40µg/ml)
Mean	0.274	-0.195	0.147
SD	0.001	0.001	0.001
% RSD	0.27	-0.53	0.73

*Mean of five replicates

Table 3 Intraday and Inter day precision data for levosalbutamol

S. no	Order	Concentration	Intra day		Inter day Precision	
			Mean Absorbance	%RSD	Mean Absorbance	%RSD
1	Zero	20	0.19	0.798	0.192	0.539
2		30	0.27	0.210	0.274	0.21
3		50	0.46	0.498	0.465	0.66
4	First	5	0.09	1.13	0.088	1.5
5		10	0.14	0.800	0.144	0.877
6		15	0.22	0.536	0.215	0.723
7	Second	40	0.146	1.044	0.147	1.03
8		50	0.28	0.361	0.280	0.552
9		60	0.38	0.154	0.3774	0.273

3.3 Accuracy

The mean % recoveries for levosalbutamol zero, first and second order were found to be 99.9, 99.87 and 100.17, respectively (Table 4). The % recovery of added drugs is well within the limits of 98-102%. It indicates the accuracy of this method.

Table 4 Recovery study for levosalbutamol

Parameters	Zero order			First order			Second order		
	80%	100%	120%	80%	100%	120%	80%	100%	120%
Amount present (µg/ml)	20	20	20	10	10	10	40	40	40
Amount Added (µg/ml)	16	20	24	8	10	12	32	40	48
Amount recovered* (µg/ml)	35.75	39.7	44.5	17.87	19.98	22.1	72.1	80.12	88.21
% Recovery	99.31	99.25	101.14	99.28	99.9	100.45	100.14	100.15	100.24
% Mean Recovery		99.9			99.87			100.17	

3.4 Analysis of market formulations

The assay result obtained by using the proposed method for the analysis of marketed formulations containing levosalbutamol. The results showed in table 5 and 6. The average content of levosalbutamol was found to be 98-100% in acceptance limit. This indicates that present method can be successfully used for the estimation of levosalbutamol.

Table 5 Assay of levosalbutamol (tablet 2mg)

Parameters	Zero order	First order	Second order
Label Claim (mg/tablet)	2	2	2
Amount Estimated (mg/tablet)*	2.01	1.994	1.990
Percentage Label Claim (%)	100.5	99.70	99.54

*Mean of three reading

Table 6 Assay of levosalbutamol (rota caps 100mcg)

Parameters	Zero order	First order	Second order
Label Claim (mcg/cap)	100	100	100
Amount Estimated (mcg/cap)*	100.53	100.2	99.86
Percentage Label Claim (%)	100.53	100.2	99.86

*Mean of three reading

4. Conclusion

Proposed study describes method for the estimation of Levosalbutamol sulphate. The method was validated and found to be simple, sensitive, accurate and precise as per ICH guidelines. The proposed method in routine quality control laboratories for determination of Levosalbutamol sulphate.

Acknowledgement

We extend our sincere thanks to Cipla Pharmaceutical Pvt, Ltd. Mumbai, India for providing gift sample of Levosalbutamol sulphate for study and Management of Alwar Pharmacy College for providing necessary facilities to carry out the research work.

References

1. Gilman AG, Limbird LE. *Goodman and Gilman's the pharmacological Basis of Therapeutics*. New York and Mc Graw Hill. **2001**; 11: 720.
2. Milgrom H. Levosalbutamol in the treatment of asthma. *Expert Opin Pharmacother*. **2006**; 7, 12: 1659-68.
3. Dave HN, Mashru RC, Thakkar AR. Simultaneous determination of salbutamol sulphate, bromhexine hydrochloride and etofylline in pharmaceutical formulations with the use of four rapid derivative spectrophotometric methods. *Anal Chem Acta*. **2007**; 597, 1: 113-20.
4. Basavaiah K, Somashekar BC, Ramakrishna V. Rapid titrimetric and spectrophotometric methods for salbutamol sulfate in pharmaceuticals using N-bromosuccinimide. *Acta Pharm*. **2007**; 57:87-98.
5. Mishra AK, Kumar M, Mishra A, Verma A, Chattopadhyay P. Validated UV spectroscopic method for estimation of salbutamol from tablet formulations. *Arch Appl Sci Res*. **2010**; 2:207-11.
6. Thulasama P, Kishore Kumar R, Venkateswarulu P. Development of new spectrophotometric methods for the estimation of levosalbutamol in tablet dosage forms. *Anal Chem Ind J*. **2009**; 8, 4:222-31.
7. Nyola N, Govindasamy J. Method development and validation of levosalbutamol in pure and rotacaps by uv-vis spectroscopy. *Int J Chemtech App*. **2012**; 1, 1:16-20.
8. De Groof J, Degroodt JM, Wyhowski de Bukanshi B, Beernaert H. Salbutamol identification in liver and urine by high performance thin layer chromatography and densitometer. *Lebensm Unters Forsch*. **1991**; 193, 2: 126-9.
9. Mc Carthy PT, Atwal S, Sykes AP, Ayres JG. Measurement of terbutaline and salbutamol in plasma by high performance liquid chromatography with fluorescence detection. *Biomed Chromatogr*. **1993**; 7, 1: 25-8.
10. Murtaza G, Ahmad M, Madni MA, Asghar MW. A new reverse phase HPLC method with fluorescent detection for the determination of salbutamol sulphate in human plasma. *Bull Chem Soc Etiop*. **2009**; 23:1-8.
11. Black SB, Hansson RC. Determination of Salbutamol and detection of other β -agonists in human postmortem whole blood and urine by GC-MS-SIM. *J Anal Toxicol*. **1999**; 23:113-8.
12. Nyola N, Govindasamy J, Yadav G, Yadav R, Gupta S, Khalilullah H. Method development and validation of levosalbutamol in pure and tablet dosage form by RP-HPLC. *J App Pharm sci*. **2012**; 2, 6: 155-8.
13. ICH Harmonised Tripartite Guideline. Text on Validation of Analytical Procedures, International Conference on Harmonization, Geneva, **1994**; 1-5.